These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 11741494)

  • 1. Risk estimation for fast neutrons with regard to solid cancer.
    Kellerer AM; Walsh L
    Radiat Res; 2001 Dec; 156(6):708-17. PubMed ID: 11741494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neutron versus gamma-ray risk estimates. Inferences from the cancer incidence and mortality data in Hiroshima.
    Kellerer AM; Nekolla E
    Radiat Environ Biophys; 1997 Jun; 36(2):73-83. PubMed ID: 9271794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk coefficient for gamma-rays with regard to solid cancer.
    Kellerer AM; Walsh L; Nekolla EA
    Radiat Environ Biophys; 2002 Jun; 41(2):113-23. PubMed ID: 12201054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of neutrons in Hiroshima. Implications for the risk estimates.
    Kellerer AM
    C R Acad Sci III; 1999; 322(2-3):229-37. PubMed ID: 10196677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of possible modifications to the DS86 dosimetry on neutron risk and relative biological effectiveness.
    Hunter N; Charles MW
    J Radiol Prot; 2002 Dec; 22(4):357-70. PubMed ID: 12546224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Solid cancer risk coefficient for fast neutrons in terms of effective dose.
    Kellerer AM; Walsh L
    Radiat Res; 2002 Jul; 158(1):61-8. PubMed ID: 12071804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Choice of model and uncertainties of the gamma-ray and neutron dosimetry in relation to the chromosome aberrations data in Hiroshima and Nagasaki.
    Rühm W; Walsh L; Chomentowski M
    Radiat Environ Biophys; 2003 Jul; 42(2):119-28. PubMed ID: 12844221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neutron relative biological effectiveness for solid cancer incidence in the Japanese A-bomb survivors: an analysis considering the degree of independent effects from γ-ray and neutron absorbed doses with hierarchical partitioning.
    Walsh L
    Radiat Environ Biophys; 2013 Mar; 52(1):29-36. PubMed ID: 23161400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Indications of the neutron effect contribution in the solid cancer data of the A-bomb survivors.
    Kellerer AM; Rühm W; Walsh L
    Health Phys; 2006 Jun; 90(6):554-64. PubMed ID: 16691103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Accounting for neutron exposure in the Japanese atomic bomb survivors.
    Cullings HM; Pierce DA; Kellerer AM
    Radiat Res; 2014 Dec; 182(6):587-98. PubMed ID: 25409123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutron relative biological effectiveness in Hiroshima and Nagasaki atomic bomb survivors: a critical review.
    Sasaki MS; Endo S; Hoshi M; Nomura T
    J Radiat Res; 2016 Nov; 57(6):583-595. PubMed ID: 27614201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer risk estimates for gamma-rays with regard to organ-specific doses. Part I: All solid cancers combined.
    Walsh L; Rühm W; Kellerer AM
    Radiat Environ Biophys; 2004 Sep; 43(3):145-51. PubMed ID: 15309386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing the Relative Biological Effectiveness of Neutrons across Organs of Varying Depth among the Atomic Bomb Survivors.
    Cordova KA; Cullings HM
    Radiat Res; 2019 Aug; 192(4):380-387. PubMed ID: 31390313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Studies of the mortality of A-bomb survivors. 9. Mortality, 1950-1985: Part 1. Comparison of risk coefficients for site-specific cancer mortality based on the DS86 and T65DR shielded kerma and organ doses.
    Shimizu Y; Kato H; Schull WJ; Preston DL; Fujita S; Pierce DA
    Radiat Res; 1989 Jun; 118(3):502-24. PubMed ID: 2727272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effective dose of A-bomb radiation in Hiroshima and Nagasaki as assessed by chromosomal effectiveness of spectrum energy photons and neutrons.
    Sasaki MS; Endo S; Ejima Y; Saito I; Okamura K; Oka Y; Hoshi M
    Radiat Environ Biophys; 2006 Jul; 45(2):79-91. PubMed ID: 16807767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer risk estimates from the combined Japanese A-bomb and Hodgkin cohorts for doses relevant to radiotherapy.
    Schneider U; Walsh L
    Radiat Environ Biophys; 2008 Apr; 47(2):253-63. PubMed ID: 18157543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiation-related posterior lenticular opacities in Hiroshima and Nagasaki atomic bomb survivors based on the DS86 dosimetry system.
    Otake M; Schull WJ
    Radiat Res; 1990 Jan; 121(1):3-13. PubMed ID: 2300666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct biological evidence for a significant neutron dose to survivors of the Hiroshima atomic bomb.
    Brenner DJ
    Radiat Res; 1996 Apr; 145(4):501-7. PubMed ID: 8600511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estimates of neutron relative biological effectiveness derived from the Japanese atomic bomb survivors.
    Little MP
    Int J Radiat Biol; 1997 Dec; 72(6):715-26. PubMed ID: 9416794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutrons at Hiroshima: how their disappearance affected risk estimates.
    Ellett WH
    Radiat Res; 1991 Oct; 128(1 Suppl):S147-52. PubMed ID: 1924742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.